Cargando…
ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer
Autores principales: | Della Corte, Carminia Maria, Gay, Carl Michael, Byers, Lauren Averett, Morgillo, Floriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355652/ https://www.ncbi.nlm.nih.gov/pubmed/30553753 http://dx.doi.org/10.1016/j.ebiom.2018.12.008 |
Ejemplares similares
-
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016) -
Early use of steroids affects immune cells and impairs immunotherapy efficacy
por: Della Corte, Carminia Maria, et al.
Publicado: (2019) -
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016) -
Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?
por: Corte, Carminia Maria Della, et al.
Publicado: (2021) -
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)